Biohaven Gains Experimental Drugs From Two New Pacts
New Haven, Conn.-based Biohaven Pharmaceutical has struck a global licensing deal with Bristol Myers Squibb (BMS) to develop and market taldefgrobep alfa, an investigational therapy for treating neuromuscular diseases.
Biohaven said it plans to launch a phase 3 study this year to evaluate the drug candidate as a treatment for spinal muscular atrophy. Financial terms of the deal were not disclosed.
Biohaven also announced plans to acquire neurology drug developer Channel Biosciences, a Knopp Biosciences subsidiary, for an estimated $100 million. Under the deal, Biohaven will gain access to Channel’s lead candidate BHV-7000, an anti-seizure medication for treatment of epilepsy.
Biohaven plans to launch a clinical trial evaluating BHV-7000 for treating epilepsy this year.
Biohaven is a clinical-stage biopharmaceutical company with proven leadership in industry and academic settings. Our portfolio is comprised of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, including rare disorders. Our progress is fueled by an entrepreneurial organizational structure and an impressive range of experience in drug development along with the confident support of top-tier biopharma investors.
Rimegepant
Biohaven has combined internal development and research with intellectual property licensed from companies and institutions including Bristol-Myers Squibb Company, AstraZeneca AB, Yale University, Catalent, ALS Biopharma LLC and Massachusetts General Hospital.
Since our initial public offering in 2017, we have made rapid progress with multiple compounds across our CGRP receptor antagonist, glutamate modulator, and myeloperoxidase (MPO) inhibitor platforms. Nurtec™ ODT (Rimegepant 75 mg) received FDA approval in February 2020 and is quickly gaining traction as the only orally disintegrating CGRP antagonist for acute treatment of migraine. At the same time, Biohaven is advancing novel acute and preventive treatments for migraine with zavegepant and rimegepant. In addition to continued exploration of our CGRP receptor antagonists , multiple clinical trials are ongoing for product candidates across our neuroinnovative platforms.
March 1, 2022
